BioSpace News Archive

9 Meters Biopharma, Inc. announced today it has joined the broad-market Russell 3000 Index and the small-cap Russell 2000 Index at the conclusion of the Russell U.S. Indexes annual reconstitution.

The growing prevalence of coronary artery diseases stands as a key factor aiding in expansion of the global antisense and RNAi therapeutics market and is likely to continue so during the forecast period set between 2020 and 2030.

Major advancements in medical science and technology, coupled with the increasing adoption of personalized medicine initiatives are likely to aid in expansion of the global DNA & RNA banking services market during the forecast period set between 2020 and 2030.

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced the appointment of Eron S. Kelly as its Corporate President.

Eisai Inc. today announced the immediate appointment of Andree Amelsberg , M.D., MBA, as Vice President, U.S. Medical Affairs, Oncology Business Group.

There has been augmented focus on personalized medicines and drug discovery utilizing in vitro methods.

Ophthalmoscopes or also called direct ophthalmoscopes are hand-held optical instrument used to inspect not just fundus or back of the eye.

Increased number of research activities in all worldwide locations is projected to boost the expansion of the global polyclonal antibody market throughout the forecast period 2020–2030.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug Application for ORIC-533 to proceed into a first-in-human clinical trial.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced the appointment of Helen Sabzevari, Ph.D. to its Board of Directors.